Read by QxMD icon Read


shared collection
19 papers 0 to 25 followers PPIs are overused and may be harmful. Choose wisely!
Daniel S Strand, Daejin Kim, David A Peura
Proton pump inhibitors (PPIs) were clinically introduced more than 25 years ago and have since proven to be invaluable, safe, and effective agents for the management of a variety of acid-related disorders. Although all members in this class act in a similar fashion, inhibiting active parietal cell acid secretion, there are slight differences among PPIs relating to their pharmacokinetic properties, metabolism, and Food and Drug Administration (FDA)-approved clinical indications. Nevertheless, each is effective in managing gastroesophageal reflux disease and uncomplicated or complicated peptic ulcer disease...
January 15, 2017: Gut and Liver
Leonardo Henry Eusebi, Stefano Rabitti, Maria Laura Artesiani, Dania Gelli, Marco Montagnani, Rocco Maurizio Zagari, Franco Bazzoli
Proton pump inhibitors are among the most commonly prescribed classes of drugs, and their use is increasing, in particular for long-term treatment, often being over-prescribed and used for inappropriate conditions. In recent years, considerable attention has been directed towards a wide range of adverse effects, and even when a potential underlying biological mechanism is plausible, the clinical evidence of the adverse effect is often weak. Several long-term side effects have been investigated ranging from interaction with other drugs, increased risk of infection, reduced intestinal absorption of vitamins and minerals, and more recently kidney damage and dementia...
July 2017: Journal of Gastroenterology and Hepatology
Pradeep Arora, Anu Gupta, Mojgan Golzy, Nilang Patel, Randolph L Carter, Kabir Jalal, James W Lohr
BACKGROUND: Acute interstitial nephritis secondary to proton pump inhibitors (PPIs) frequently goes undiagnosed due to its subacute clinical presentation, which may later present as chronic kidney disease (CKD). We investigated the association of PPI use with the development of CKD and death. METHODS: Two separate retrospective case-control study designs were employed with a prospective logistic regression analysis of data to evaluate the association of development of CKD and death with PPI use...
August 3, 2016: BMC Nephrology
Willy Gomm, Klaus von Holt, Friederike Thomé, Karl Broich, Wolfgang Maier, Anne Fink, Gabriele Doblhammer, Britta Haenisch
IMPORTANCE: Medications that influence the risk of dementia in the elderly can be relevant for dementia prevention. Proton pump inhibitors (PPIs) are widely used for the treatment of gastrointestinal diseases but have also been shown to be potentially involved in cognitive decline. OBJECTIVE: To examine the association between the use of PPIs and the risk of incident dementia in the elderly. DESIGN, SETTING, AND PARTICIPANTS: We conducted a prospective cohort study using observational data from 2004 to 2011, derived from the largest German statutory health insurer, Allgemeine Ortskrankenkassen (AOK)...
April 2016: JAMA Neurology
Benjamin Lazarus, Yuan Chen, Francis P Wilson, Yingying Sang, Alex R Chang, Josef Coresh, Morgan E Grams
IMPORTANCE: Proton pump inhibitors (PPIs) are among the most commonly used drugs worldwide and have been linked to acute interstitial nephritis. Less is known about the association between PPI use and chronic kidney disease (CKD). OBJECTIVE: To quantify the association between PPI use and incident CKD in a population-based cohort. DESIGN, SETTING, AND PARTICIPANTS: In total, 10,482 participants in the Atherosclerosis Risk in Communities study with an estimated glomerular filtration rate of at least 60 mL/min/1...
February 2016: JAMA Internal Medicine
Matthew A Jackson, Julia K Goodrich, Maria-Emanuela Maxan, Daniel E Freedberg, Julian A Abrams, Angela C Poole, Jessica L Sutter, Daphne Welter, Ruth E Ley, Jordana T Bell, Tim D Spector, Claire J Steves
OBJECTIVE: Proton pump inhibitors (PPIs) are drugs used to suppress gastric acid production and treat GI disorders such as peptic ulcers and gastro-oesophageal reflux. They have been considered low risk, have been widely adopted, and are often over-prescribed. Recent studies have identified an increased risk of enteric and other infections with their use. Small studies have identified possible associations between PPI use and GI microbiota, but this has yet to be carried out on a large population-based cohort...
May 2016: Gut
Floris Imhann, Marc Jan Bonder, Arnau Vich Vila, Jingyuan Fu, Zlatan Mujagic, Lisa Vork, Ettje F Tigchelaar, Soesma A Jankipersadsing, Maria Carmen Cenit, Hermie J M Harmsen, Gerard Dijkstra, Lude Franke, Ramnik J Xavier, Daisy Jonkers, Cisca Wijmenga, Rinse K Weersma, Alexandra Zhernakova
BACKGROUND AND AIMS: Proton pump inhibitors (PPIs) are among the top 10 most widely used drugs in the world. PPI use has been associated with an increased risk of enteric infections, most notably Clostridium difficile. The gut microbiome plays an important role in enteric infections, by resisting or promoting colonisation by pathogens. In this study, we investigated the influence of PPI use on the gut microbiome. METHODS: The gut microbiome composition of 1815 individuals, spanning three cohorts, was assessed by tag sequencing of the 16S rRNA gene...
May 2016: Gut
Daniel E Freedberg, Nora C Toussaint, Sway P Chen, Adam J Ratner, Susan Whittier, Timothy C Wang, Harris H Wang, Julian A Abrams
We conducted an open-label crossover trial to test whether proton pump inhibitors (PPIs) affect the gastrointestinal microbiome to facilitate Clostridium difficile infection (CDI). Twelve healthy volunteers each donated 2 baseline fecal samples, 4 weeks apart (at weeks 0 and 4). They then took PPIs for 4 weeks (40 mg omeprazole, twice daily) and fecal samples were collected at week 8. Six individuals took the PPIs for an additional 4 weeks (from week 8 to 12) and fecal samples were collected from all subjects at week 12...
October 2015: Gastroenterology
Nigam H Shah, Paea LePendu, Anna Bauer-Mehren, Yohannes T Ghebremariam, Srinivasan V Iyer, Jake Marcus, Kevin T Nead, John P Cooke, Nicholas J Leeper
BACKGROUND AND AIMS: Proton pump inhibitors (PPIs) have been associated with adverse clinical outcomes amongst clopidogrel users after an acute coronary syndrome. Recent pre-clinical results suggest that this risk might extend to subjects without any prior history of cardiovascular disease. We explore this potential risk in the general population via data-mining approaches. METHODS: Using a novel approach for mining clinical data for pharmacovigilance, we queried over 16 million clinical documents on 2...
2015: PloS One
Orlaith B Kelly, Catherine Dillane, Stephen E Patchett, Gavin C Harewood, Frank E Murray
UNLABELLED: Proton pump inhibitors (PPIs) are used to treat upper gastrointestinal tract disorders. Their efficacy and perceived safety have led to widespread prescription. This is not without effect, in terms of adverse events and resource utilization. AIM: To prospectively assess oral PPI prescription in hospitalized patients. METHODS: PPI prescription in consecutive hospitalized patients was assessed. Indication and dose were assessed by patient interview and medical record review...
August 2015: Digestive Diseases and Sciences
Jeffrey F Barletta, David A Sclar
INTRODUCTION: Proton pump inhibitors (PPI) have been linked to Clostridium difficile infection (CDI) but there are few data specific to ICU patients. We evaluated duration of PPI exposure as a potential risk factor for hospital-acquired CDI in the ICU. METHODS: This retrospective, case-control study was conducted using the Multiparameter Intelligent Monitoring in Intensive Care II database, a large publically available database of more than 35,000 ICU patients. Adult patients with CDI were identified using the ICD-9 code for Clostridium difficile listed as a secondary diagnosis...
December 24, 2014: Critical Care: the Official Journal of the Critical Care Forum
Chia-Jen Shih, Yung-Tai Chen, Shuo-Ming Ou, Szu-Yuan Li, Tzeng-Ji Chen, Shuu-Jiun Wang
BACKGROUND: There is substantial debate regarding the development of acute coronary syndrome in patients using proton pump inhibitors (PPIs) combined with clopidogrel. However, data remain limited to address the effect of PPIs alone on the subsequent risk of myocardial infarction (MI). We aimed to explore the subsequent risk of MI in PPI users who had no previous history of MI. METHODS: The records of inpatients and outpatients with PPI prescriptions were retrieved from the Taiwan National Health Insurance Research Database between 2000 and 2009...
November 15, 2014: International Journal of Cardiology
Jonathan Zipursky, Erin M Macdonald, Simon Hollands, Tara Gomes, Muhammad M Mamdani, J Michael Paterson, Nina Lathia, David N Juurlink
BACKGROUND: Some evidence suggests that proton pump inhibitors (PPIs) are an under-appreciated risk factor for hypomagnesemia. Whether hospitalization with hypomagnesemia is associated with use of PPIs is unknown. METHODS AND FINDINGS: We conducted a population-based case-control study of multiple health care databases in Ontario, Canada, from April 2002 to March 2012. Patients who were enrolled as cases were Ontarians aged 66 years or older hospitalized with hypomagnesemia...
September 2014: PLoS Medicine
Joshua R Lewis, Deka Barre, Kun Zhu, Kerry L Ivey, Ee Mun Lim, Jeff Hughes, Richard L Prince
Proton pump inhibitors (PPIs) are widely used in the elderly. Recent studies have suggested that long-term PPI therapy is associated with fractures in the elderly, however the mechanism remains unknown. We investigated the association between long-term PPI therapy ≥1 year and fracture risk factors including bone structure, falls, and balance-related function in a post hoc analysis of a longitudinal population-based prospective cohort of elderly postmenopausal women and replicated the findings in a second prospective study of falling in elderly postmenopausal women...
November 2014: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
Mei-Ling Blank, Lianne Parkin, Charlotte Paul, Peter Herbison
The magnitude of the suspected increase in risk of acute interstitial nephritis among proton pump inhibitor users is uncertain. Here, we conducted a nested case-control study using routinely collected national health and drug dispensing data in New Zealand to estimate the relative and absolute risks of acute interstitial nephritis resulting in hospitalization or death in users of proton pump inhibitors. The cohort included 572,661 patients without a history of interstitial nephritis or other renal diseases who started a new episode of proton pump inhibitor use between 2005 and 2009...
October 2014: Kidney International
Kristian B Filion, Dan Chateau, Laura E Targownik, Andrea Gershon, Madeleine Durand, Hala Tamim, Gary F Teare, Pietro Ravani, Pierre Ernst, Colin R Dormuth
OBJECTIVE: Previous observational studies suggest that the use of proton pump inhibitors (PPIs) may increase the risk of hospitalisation for community-acquired pneumonia (HCAP). However, the potential presence of confounding and protopathic biases limits the conclusions that can be drawn from these studies. Our objective was, therefore, to examine the risk of HCAP with PPIs prescribed prophylactically in new users of non-steroidal anti-inflammatory drugs (NSAIDs). DESIGN: We formed eight restricted cohorts of new users of NSAIDs, aged ≥40 years, using a common protocol in eight databases (Alberta, Saskatchewan, Manitoba, Ontario, Quebec, Nova Scotia, US MarketScan and the UK's General Practice Research Database (GPRD))...
April 2014: Gut
Deborah Patterson Burdsall, Hanzel C Flores, Jill Krueger, Sandra Garretson, Martin J Gorbien, Amy Iacch, Vicky Dobbs, Theodore Homa
OBJECTIVES: The primary objective of this study was to identify proton pump inhibitor (PPI) prescribing patterns in a population of older adults admitted to 22 Midwestern skilled long term care facilities (LTCF) with medical coverage provided by the US Medicare Part A program. The relationship between PPI prescribing patterns and specific ICD-9 diagnostic codes and symptoms management was examined. The long-term objective is appropriate PPI prescription guidance through the development of evidence- and regulation-based pharmacy formulary and policy practices, as well as practical prescribing guidance for practitioners who are supported by this pharmacy...
June 2013: Journal of the American Medical Directors Association
Marcello Maggio, Andrea Corsonello, Gian Paolo Ceda, Chiara Cattabiani, Fulvio Lauretani, Valeria Buttò, Luigi Ferrucci, Stefania Bandinelli, Angela Marie Abbatecola, Liana Spazzafumo, Fabrizia Lattanzio
IMPORTANCE: The use of proton pump inhibitors (PPIs) has rapidly increased during the past several years. However, concern remains about risks associated with their long-term use in older populations. OBJECTIVE: To investigate the relationship between the use of PPIs and the risk of death or the combined end point of death or rehospitalization in older patients discharged from acute care hospitals. DESIGN: We investigated the relationship between PPI use and study outcomes using time-dependent Cox proportional hazards regression in patients 65 years or older discharged from acute care medical wards from April 1 to June 30, 2007...
April 8, 2013: JAMA Internal Medicine
Mariko Teramura-Grönblad, J Simon Bell, Minna M Pöysti, Timo E Strandberg, Jouko V Laurila, Reijo S Tilvis, Helena Soini, Kaisu H Pitkälä
OBJECTIVES: To (1) explore clinical and demographic characteristics of users and nonusers of PPIs in 3 cohorts of institutionalized older people in Finland, and (2) compare the risk of death associated with use of PPIs in each setting. DESIGN: Cross-sectional assessment of 3 institutionalized cohorts with 1-year follow-up of all-cause mortality. SETTING AND PARTICIPANTS: A total of 1389 residents of 69 assisted living facilities (first cohort), 1004 residents of long term care hospitals (second cohort), and 425 residents in acute geriatric wards or in nursing homes (third cohort)...
June 2012: Journal of the American Medical Directors Association
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"